

A large, stylized pink ribbon is positioned diagonally across the upper right portion of the image. The ribbon is a vibrant pink color and is tied in a loop, with its ends trailing off towards the bottom right corner. The background is a soft, light pink gradient with subtle, wavy lines.

# BREAST CANCER & SURVIVORSHIP IN THE 21ST CENTURY:

Less is More, More or Less

Saturday, June 15, 2019  
7:00am – 5:00pm

Albany Marriott Hotel  
189 Wolf Road, Albany, NY 12205

PROUDLY HOSTED BY  
NEW YORK ONCOLOGY HEMATOLOGY



ACCREDITED  
PROVIDER



ACTIVITY  
PLANNED BY



# BREAST CANCER & SURVIVORSHIP IN THE 21ST CENTURY:

Less is More, More or Less

## **PRESENTATION DOWNLOAD**

The accredited content presented during the conference will be posted online for viewing and download within 30 days after the conference. An email will be sent to all participants with viewing and download instructions. Not all presentations will be shared due to reprint and permission restrictions.



## **INTERNET ACCESS**

Complimentary Wi-Fi is available using code “Marriott2019” to log in.



## **HOW TO CLAIM CREDIT**

### **Physicians and Allied Health Professionals:**

- Sign in at the registration desk if you have not done so already.
- You will be emailed instructions for completing the post-test, program evaluation, claiming credit and printing your certificate within 7 days.



Dear Colleagues, Health Care Professionals, Friends and Patients:

Today New York Oncology Hematology is proudly launching the first breast cancer and survivorship symposium in the Albany area. ***Breast Cancer & Survivorship in the 21st Century: Less is More, More or Less*** will focus on the multimodality decision making and approach in treating breast cancer patients based on all the recent clinical research and bench science that has been translated to the patient arena.

Today we are bringing together a group of nationally and internationally recognized speakers that will address the heterogeneity of breast cancer, the diagnosis, treatment and survivorship of a disease that has multiple faces and multiple targeted approaches for treatment and potential cure. Breast cancer is not biased, and therefore not particular to any age group, ethnicity or gender. Targeting the individual patient's specific diagnosis, molecular biology and identifying the goals of treatment has engineered a blueprint for individualizing therapy to the individual patient. Major progress has been made over the past twentieth century improving survival and decreasing mortality from breast cancer and continues to grow exponentially in this twenty-first century. Our patients are benefiting, our standards of care globally improving, and quality of care as well as quality of life has continued to improve.

The conversation between scientists, surgeons, medical oncologists, radiation oncologists and our ancillary experts help support our patients physically, emotionally and psychologically, as well as their loved ones. The conversation is facilitated by symposiums such as this one and at the end of the day it is a conversation about and with our patients.

To our organizing committee, grantors, exhibitors, medical community and patients, thank you for what promises to be the first of many such symposiums. Thank you for attending and sharing your knowledge, experiences and education.

The dream is to continue these educational venues until we see breast cancer disappear and they are no longer needed. Today is the beginning of the dream.

Sincerely,

A handwritten signature in black ink, appearing to read 'M Theodoulou', with a stylized, flowing script.

Maria Theodoulou, MD, Program Chair  
New York Oncology Hematology

# BREAST CANCER & SURVIVORSHIP IN THE 21ST CENTURY:

Less is More, More or Less

## PROGRAM AGENDA

### 7:00-8:00am BREAKFAST, EXHIBITS, AND REGISTRATION

8:00-8:15am Introduction —*Dr. Ira Zackon and Dr. Maria Theodoulou*

8:15-8:45am The Surgeon's Mission—Cancer and Cosmesis —*Dr. Loren Rourke*

8:45-9:15am Breast Imaging: Current & Advanced Techniques —*Dr. Beth Whiteside*

9:15-9:45am Controversies in Breast Radiotherapy:  
Radiation Therapy After Neoadjuvant Chemotherapy —*Dr. Todd Doyle*

### 9:45-10:00am BREAK & EXHIBITS

10:00-10:30am Updates for the Management of TNBC —*Dr. Tiffany Traina*

10:30-11:00am Updates On Treatment Of Early Stage HER2/neu  
Positive Breast Cancer —*Dr. Chau Dang*

11:00-11:30am Adjuvant Therapy for Premenopausal Hormone  
Receptor Positive Breast Cancer —*Dr. Marc Citron*

### 11:30-1:00pm LUNCH & EXHIBITS

11:45-12:45pm **NON-ACCREDITED ANCILLARY EVENT**  
A Case-Based Discussion: In the HER2+  
Early Breast Cancer Setting —*Eleftherios Mamounas, MD*

1:15-1:45pm Sexual/Vulvovaginal Health and Cancer:  
What We Have Learned and What You Need to Know —*Dr. Jeanne Carter*

1:45-2:15pm Sex and Intimacy: Have the Conversation —*Dr. Bridget Finn*

2:15-2:45pm Oncogenetics —*Dr. Elizabeth Poynor*

### 2:45-3:00pm BREAK & EXHIBITS

3:00-3:45pm **SURVIVORSHIP AWARD/ LECTURE**  
HER2/neu Breast Cancer—Focusing Inside of the Cell,  
Nerlyx in Early, Late, and CNS Disease —*Dr. Francis Arena*

### 3:45-5:00pm SURVIVORSHIP PANEL



## PROGRAM OVERVIEW

Advances in breast cancer health have been growing exponentially during the twenty-first century and identification of novel therapeutic strategies have led to improved surgical and radiation outcomes. Actionable targets have identified smarter systemic therapies with improved, disease-free, overall survival benefits. In addition to awareness, addressing the health, emotional, and physical well-being of patients after breast cancer treatment have improved the overall quality of life for the patient and their families. As breast cancer is a multimodal disease, the purpose of this conference is to present the multiple facets that constitute the individual patient's diagnosis, management, and treatment. The goal of this conference is to educate the medical and global community in a forum to foster communication that will benefit the individual patient as well as the community.

## TARGET AUDIENCE

The morning program will address the updates in diagnosing, treating, and managing the multiple breast cancer diagnoses we encounter daily. Medical, surgical, and radiation oncologists, as well as primary care physicians, gynecologists, medical professionals, and health care professionals with an interest in breast cancer and its survivorship are invited. The afternoon program will address lifestyle issues that can benefit the emotional, physical, and sexual well-being of the patient during treatment, after treatment, and in survivorship.

## LEARNING OBJECTIVES

After completing this activity, participants should be better prepared to:

- Review the modern surgical approaches addressed in the patient encounter
- Discuss updates in advanced breast cancer imaging for earlier detection
- Identify systemic therapeutic advances in hormone receptor-positive, HER2/neu overexpressing and triple negative breast cancer
- Review advances in radiation therapy and outcomes
- Discuss the multiple aspects of surviving breast cancer, including the physical and emotional hurdles and improving sexual health

## FEE INFORMATION

There is no fee for this educational activity.

## ACCREDITATION INFORMATION

### Physician and Allied Health Professional Accreditation



This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Emergency Medical Education and myMedEd, Inc.

The Center for Emergency Medical Education (CEME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Center for Emergency Medical Education (CEME) designates this live activity for a maximum of 5.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Center for Emergency Medical Education (CEME) designates this live activity for a maximum of 5.25 hours of participation for continuing education for allied health professionals.

### Disclosure of Faculty Financial Interests or Relationships:

It is the policy of the Center for Emergency Medical Education (CEME) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities, and that all contributors present information in an objective, unbiased manner without endorsement or criticism of specific products or services and that the relationships that contributors disclose will not influence their contributions. In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Center for Emergency Medical Education (CEME) requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. All individuals in a position to control the content of this CME activity have indicated that he/she has no relevant financial relationships, which, in the context of this CME activity, could be perceived as a potential conflict of interest. Complete disclosure of relevant (or no) financial relationships will be made to learners prior to the beginning of the CME activity. All faculty pictured may not be at all scheduled course dates.

## PLANNING COMMITTEE

---

### **Maria Theodoulou, MD (Course Chair & Moderator)**

Medical Oncologist  
New York Oncology Hematology  
Albany, NY

### **Ira Zackon, MD**

Medical Hematology and Oncology Director  
NYOH Hematology Stem Cell Transplant Program  
Hematologist/Oncologist NYOH, PC  
Clinical Assistant Professor, Albany Medical College  
Albany, NY

## FACULTY

---

### **Francis Arena, MD**

Director, NYU Langone Arena Oncology  
Clinical Professor, NYU Health Medical College  
Lake Success, NY

### **Jeanne Carter, PhD**

Head, Female Sexual Medicine and  
Women's Health Program  
Memorial Sloan Kettering Cancer Center  
New York, NY

### **Marc L. Citron, MD**

Clinical Professor of Medicine  
Zucker School of Medicine at Hofstra/Northwell  
Chair, Emeritus of Oncological Services  
Chief Breast Services  
Lake Success Oncology  
Lake Success, NY

### **Chau T. Dang, MD**

Chief, Westchester Medical Oncology Service  
Associate Attending, Breast Medicine Service  
Memorial Sloan Kettering Cancer Center  
New York, NY

### **Todd Doyle, MD**

Director of Radiation Therapy  
New York Oncology Hematology  
Albany, NY

### **Bridget M. Finn, PhD**

Founder and President  
Capital Region Center for Sexual Health, LLC  
Troy, NY

### **Elizabeth Poynor, MD, PhD**

Principal  
Poynor Health New York  
New York, NY

### **Loren L. Rourke, MD, MHCM, FACS**

Chief Surgical Officer, US Oncology Network  
McKesson Pharmaceutical Services  
and Solutions  
The Woodlands, TX

### **Tiffany A. Traina, MD**

Associate Attending Physician  
Clinical Director, Breast Medicine Service  
Section Head, Triple Negative Breast Cancer  
Clinical Research Program  
Associate Professor  
Weill Cornell Medical College  
New York, NY

### **Beth E. Whiteside, MD**

Assistant Professor of Radiology  
Medical Director  
Albany Medical Center  
Albany, NY

**The Survivorship panel for patients, families, lay community as well as medical professionals will consist of the following panel:**

Dr. Francis Arena  
Dr. Maria Theodoulou  
Dr. Tia Olds  
Dr. Karen Tedesco  
Dr. Bridget Finn  
Kathy Hena

Deborah Dzingile  
Dr. Rufus Collea  
Dr. Loren Rourke  
Dr. Gabriel Kaufman  
Dr. Anna Boguniewicz  
Patient Advocates



## PLANNING COMMITTEE BIOGRAPHIES

---



### **Maria Theodoulou, MD (Course Chair & Moderator)**

Dr. Theodoulou is recognized internationally for her breast cancer research. Prior to joining NYOH, she was an attending physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center on the Breast Medicine Service, and a Professor of Medicine at the Joan and Sanford Weill Medical College of Cornell University, both in New York City. Her research has included HER2neu directed clinical research, conjugated antibody research, androgen receptor positive triple negative targeted clinical trials, feasibility and phase 3 trials in the elderly in the early breast cancer setting and novel molecules in advanced breast cancer. She has mentored multiple residents and fellows, and has lectured extensively in the U.S. and chaired international symposiums and lectured in Bangkok, India, Japan, Hong Kong, and Europe. She has received multiple awards, as well as a Lifetime Achievement Award from the country of Cyprus, the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation, as well as the Lifetime Achievement Award from the Hellenic Medical Society in New York in 2016.

Dr. Theodoulou, a long time weekender in the Southern Berkshires where she and her husband have owned a home, moved up to the country full time in 2016. Unable to give up her passion for taking care of patients, she joined NYOH seeing patients part time in Albany and Hudson, New York. She is now collaborating with her colleagues to continue developing a center of excellence for the treatment of breast cancer and addressing women's health issues.



### **Ira Zackon, MD**

Ira Zackon, MD, is a Hematologist/ Oncologist and Director of the Stem Cell Transplant Program and President of New York Oncology Hematology, PC (NYOH) and assistant clinical professor at Albany Medical College in Albany, New York.

After earning a medical degree in 1986 from McGill University in Montreal, Quebec, Canada, he completed an internship and residency in medicine at Royal Victoria Hospital in Montreal in 1987. Dr. Zackon completed fellowships in Hematology/Medical Oncology at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (1990-1992), and Northwestern University Medical Center, Chicago, Illinois (1992-1994).

At NYOH, Dr. Zackon has developed the practice's autologous stem cell transplant program, expanded collaborative care for allogeneic bone marrow transplant patients at NYOH with regional transplant centers, and focused NYOH participation in research trials in the hematologic malignancies through the US Oncology Network and the Blood Cancer Research Partnership in association with the Dana-Farber Cancer Institute in Boston, Massachusetts.

## FACULTY BIOGRAPHIES

---



### **Francis Arena, MD**

Francis P. Arena, MD, FACP received his Bachelor of Science Degree from Fordham University and his Medical Degree from Cornell University Medical College. His internship and residency were carried out at New York Hospital/Memorial Hospital, after which Dr. Arena served as Chief Medical Resident and later as Hematology/Oncology Fellow at the Memorial Sloan-Kettering Cancer Center. He was also assistant to Chairman of Medicine for education at Memorial Sloan Kettering Cancer Center. He is Board Certified in Internal Medicine and in Medical Oncology. Today Dr. Arena is Clinical Professor of Medicine at New York University and Adjunct Clinical Assistant Professor of Medicine at Cornell University Medical College. He is the Director of the NYU Langone Arena Oncology Center in Lake Success, NY. Because of his keen interest in cancer research, Dr. Arena helped establish and is the president of the SASS Foundation for Medical Research, which supports medical fellows at a number of hospitals. He is on the Advisory Board of "1 in 9", the Breast Cancer Coalition, and serves as a consultant for numerous pharmaceutical companies. Dr. Arena is widely published and has lectured extensively in his field. He is an Assistant Editor of the journal Oncology and previously on

*continued →*



the Editorial Board of the Community Oncology journal. Dr. Arena has been the recipient of multiple awards and citations for his work in oncology and breast cancer. Some of these awards include the David award given by Networking magazine, The Eileen Dryer Award by the Sass Foundation, the Il Leone de San Marco award in medicine by the Italian -American league of Westchester and the Bronx and has been cited in repeated years as one of the top oncologists in the New York Metropolitan area by the Castle Connolly magazines and Newsday. Frank lives with his wife and wonderful children in Long Island, NY.



### **Jeanne Carter, PhD**

Dr. Carter currently serves as the Head of the Female Sexual Medicine and Women's Health Program, Gynecology Service, Department of Surgery. This program provides individual interventions to female cancer patients, women at risk of cancer, and survivors coping with the physical and emotional challenges of cancer treatment. She has a dual appointment in the Department of Surgery and Department of Psychiatry as an Associate Attending Psychologist. In addition she had an active role in the cooperative group setting of the Gynecologic Oncology Group (GOG), participating as a member of the GOG Quality of Life and Health Outcomes Research Committee (2004-2013), Cancer Prevention and Control (CPC) Committee (2010-2014), and with the merger of the cooperative groups currently serves on the NRG Oncology Group's Patient-Centered Outcomes Research (PCOR) committee and NRG Cancer Prevention and Control (CPC) Committee. Some of her research includes serving as the Quality of Life Study Chair on GOG 242, a clinical trial prospectively investigating the incidence and quality of life impact of lower extremity lymphedema in women undergoing radical surgery for gynecologic malignancy (1R01CA162139-01A2; PI, Barakat), recipient of a grant from the Lance Armstrong Foundation to examine the psychosexual impact of impaired fertility in female cancer survivors (Carter J, et al. J Cancer Survivorship 2010 Sep;4(3):236-46.) and the PI on a clinical trial investigating a non-hormonal vaginal moisturizer in postmenopausal cancer survivors experiencing estrogen deprivation symptoms". Her academic career has focused on cancer, symptom management and treatment effects, QOL and survivorship as a lecturer, author, clinician and researcher on multiple protocols both as PI and Co-PI.



### **Marc L. Citron, MD**

Recognized for his innovative research in breast cancer and a diverse group of malignancies, Dr. Citron is acknowledged as an authority in the treatment of cancer. His experience in clinical cancer care spans over 40 years. Dr. Citron received his undergraduate degree from Brandeis University. After completing medical school at Wayne State University and training in internal medicine at Georgetown University, Dr. Citron was promoted to Chief Medical Resident and later awarded the Daryl Rubenstein Fellowship in Medical Oncology at Georgetown's Vincent Lombardi Cancer Center.

Realizing the need for improved methods of treatment, Dr. Citron dedicated his career to cancer research and therapy. Dr. Citron was Head of Long Island Jewish Medical Center's Medical Oncology Section for 13 years. In 1997 he became Chief of Oncology at ProHEALTH and Clinical Professor of Medicine at the Albert Einstein College of Medicine. In 2011 he became Clinical Professor of Medicine, Hofstra North Shore LIJ School of Medicine, currently Hofstra Northwell School of Medicine at Hofstra University. In 2012 Dr. Citron was appointed Director of Cancer Services at ProHEALTH Care Associates.

As principal investigator in the early 2000s for National Cancer Institute Protocol C9741, Dr. Citron pioneered a groundbreaking study that established dose-dense chemotherapy, a treatment that applies postoperative chemotherapy in a shorter, more intense schedule. Dose-Dense chemotherapy is now one of the leading pre and postoperative treatments for breast cancer because of its superior efficacy and reduced toxicity.





### **Chau T. Dang, MD**

With an interest in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer, Dr. Dang focuses on developing more effective and less toxic treatment strategies for women with this disease. Her research and an investigator-initiated trial at Memorial Sloan Kettering has led to the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer. A second investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. Dr. Dang and her colleagues are currently leading other research trials, both locally and internationally that focus on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, she studies cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.

Dr. Dang is board-certified in internal medicine and medical oncology with clinical expertise in breast cancer. She received her MD at the Medical University of South Carolina followed by Internal Medicine Residencies at Allegheny General Hospital/Medical College of Pennsylvania and Fellowships in Hematology/Oncology at Memorial Sloan Kettering Cancer Center.



### **Todd Doyle, MD**

Dr. Doyle was trained as a radiation oncologist at the Mallinckrodt Institute of Radiology and the Hospital of the University of Pennsylvania. He is currently the director of radiation oncology and a board member with New York Oncology Hematology PC. He is a Susan G. Komen Honoree for the treatment of breast cancer and has published on the treatment of breast cancer in the International Journal of Radiation Oncology Biology and Physics. He has served as a written and oral examiner for the American Board of Radiology as well as on numerous other academic and administrative committees. Current interests include novel modalities in the delivery of radiation therapy including SRS and SBRT in addition to the treatment of breast cancer.



### **Bridget M. Finn, PhD**

Dr. Bridget M. Finn is the Founder and President of the Capital Region Center for Sexual Health, LLC, located in downtown Troy, New York. Dr. Finn is a sexual health expert with over thirty years of experience working with women and men around sexuality and intimacy related concerns. As a sex therapist, educator, author and researcher, she has helped her clients improve their sex lives, enjoy an expanded level of intimacy, and build strong relationships in and out of the bedroom.

After obtaining a Master's Degree in Health Education from Russell Sage College, and a Doctorate Degree in Human Sexuality from the University of Pennsylvania, she completed her advanced clinical training and certification in sex and relationship therapy at the Council for Relationships, the nation's oldest and largest counseling agency located in Philadelphia.



### **Elizabeth Poynor, MD, PhD**

Dr. Elizabeth A. Poynor is a gynecologic oncologist and advanced pelvic surgeon, with a deep understanding of women's health. Dr. Poynor graduated magna cum laude from Princeton University in 1984, graduated from Columbia College of Physicians and Surgeons in 1988, and completed her residency training in Obstetrics and Gynecology at the University of Pennsylvania in 1992. She completed her fellowship in gynecologic oncology in 1995 at Memorial Sloan-Kettering Cancer Center, and remained on the surgical attending staff until 2006, when Dr. Poynor established her private practice. While developing and maintaining a busy surgical practice as an Assistant Attending Surgeon at Memorial Sloan-Kettering Cancer Center and Assistant Professor of Obstetrics and Gynecology at Cornell Weill Graduate School of Medical Sciences, she also obtained a PhD in cell biology and genetics from Cornell. Dr. Poynor is Board Certified in Obstetrics and Gynecology and Gynecologic Oncology.

*continued →*



Dr. Poynor has been named a Castle Connolly Top Doctor in New York each year from 2007-2018 and is listed in the Best Doctors in America. Dr. Poynor has co-authored numerous publications and book chapters on topics in gynecology and gynecologic oncology, and has lectured nationally, internationally and through the national media. As a surgeon scientist, her work involved translating basic science principles into clinically meaningful treatments and she served as Director of Translational Research for the Gynecology Service at Memorial Sloan-Kettering Cancer Center. Dr. Poynor has also served as an investigator in numerous clinical trials relating to the surgical, medical, and biologic treatment of gynecologic cancers and has participated in national leadership positions in gynecologic oncology including the Committee on Experimental Medicine in the Gynecologic Oncology Group. She was the first gynecologic surgeon at Lenox Hill Hospital to employ robotic surgery and maintains an appropriately high surgical volume of robotic surgery cases. She currently performs surgery at NYU Langone Medical Center in New York, and Northwell Health Lenox Hill Hospital.



### **Loren L. Rourke, MD, MHCM, FACS**

Originally from the Northeast, Dr. Loren Rourke is a fellowship-trained breast surgical oncologist with extensive experience building comprehensive multidisciplinary breast programs in community, academic, and hybrid environments. She has dedicated her career to ensuring patients receive exceptional care in a compassionate and informative atmosphere. She completed her general surgery residency at the University of Tennessee in Knoxville, the Susan G. Komen Interdisciplinary Breast Fellowship at UT MD Anderson Cancer Center, and most recently a Master's in Healthcare Management from the Harvard T.C. Chan School of Public Health as part of her pursuit to broaden her business understanding of the current healthcare landscape. She currently serves as the first-ever Chief Surgical Officer for McKesson's US Oncology Network, a role dedicated to the improvement and strategic development of surgical services across the Network.



### **Tiffany A. Traina, MD**

Dr. Tiffany A. Traina is an Associate Attending Physician and Clinical Director of the Breast Medicine Service at Memorial Sloan Kettering. She serves as the Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is also Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancers, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor in breast cancers. Dr. Traina has served on numerous ASCO committees including the Scientific Program Committee for the ASCO Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and she is the Chair-elect for the ASCO Membership Committee 2019-2020. She is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Dr. Traina is a graduate of the 2016-2017 ASCO Leadership Development Program and now serves as an advisor on the Breast Cancer Guidelines Advisory Group. Her research efforts have earned her the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation and awards from the Breast Cancer Research Foundation. She has received recognition for teaching from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine and the Hero Award from the Triple Negative Breast Cancer Foundation.



### **Beth E. Whiteside, MD**

Dr. Beth Whiteside is medical director of Albany Medical Center's Breast Care Center, which is accredited as a Breast Imaging Center of Excellence by the American College of Radiology. She also serves as assistant professor of radiology at Albany Medical College, and is a radiologist with ImageCare of Community Care Physicians, P.C. Dr. Whiteside was fellowship trained in breast imaging at Duke University. She completed her residency training at Hartford Hospital, and an internship at the then Mary Imogene Bassett Hospital in Cooperstown. She received her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences.



## Less is More, More or Less

## This image shows a full page of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There is no handwriting or other markings on the paper.

# BREAST CANCER & SURVIVORSHIP IN THE 21ST CENTURY:

Less is More, More or Less

*Breast Cancer & Survivorship in the 21st Century: Less is More, More or Less*

is supported by an educational grant from:

**Puma Biotechnology**

The non-CME Ancillary Event titled: *A Case-Based Discussion:  
In The HER2+ Early Breast Cancer Setting* is provided by:

**Genentech**

---

Thank you to the following sponsors and exhibitors of:

*Breast Cancer & Survivorship in the 21st Century: Less is More, More or Less*

## **GOLD SPONSORSHIP:**

**Novartis Oncology  
Pfizer Oncology**

## **SILVER SPONSORSHIP:**

**Celgene Corporation  
Genentech**

## **BRONZE SPONSORSHIP:**

**AbbVie, Inc.  
Ambry Genetics Corporation  
Amgen, Inc.  
AstraZeneca US  
Boehringer Ingelheim Pharmaceuticals, Inc.  
Genoptix, A NeoGenomics Company  
Lilly USA, LLC**

**Merck & Co, Inc.  
Myriad Genetic Laboratories  
Puma Biotechnology  
Sanofi-Genzyme  
Susan G. Komen® Upstate NY  
Teva Pharmaceuticals Industries Ltd.**

PROUDLY HOSTED BY  
NEW YORK ONCOLOGY HEMATOLOGY



ACTIVITY  
PLANNED BY

